These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 17171317)
1. [Recurrent disease after liver transplantation. A therapeutic dilemma or treatable?]. Beckebaum S; Cicinnati VR; Broelsch CE; Gerken G Med Klin (Munich); 2006 Dec; 101(12):939-50. PubMed ID: 17171317 [TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. Casanovas T; Argudo A; Peña-Cala MC Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242 [TBL] [Abstract][Full Text] [Related]
8. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Saab S; Hunt DR; Stone MA; McClune A; Tong MJ Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909 [TBL] [Abstract][Full Text] [Related]
9. Management of recurrent hepatitis C after liver transplantation: a concise review. Szabo G; Katz E; Bonkovsky HL Am J Gastroenterol; 2000 Sep; 95(9):2164-70. PubMed ID: 11007212 [TBL] [Abstract][Full Text] [Related]
10. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166 [TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12. Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783 [TBL] [Abstract][Full Text] [Related]
12. Long-term results of liver transplant in patients with chronic viral hepatitis-related liver disease in Singapore. Wai CT; Da Costa M; Sutedja D; Lee YM; Lee KH; Tan KC; Isaac J; Wee A; Prabhakaran K; Lim SG Singapore Med J; 2006 Jul; 47(7):588-91. PubMed ID: 16810429 [TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Fernández I; Ulloa E; Colina F; Abradelo M; Jiménez C; Gimeno A; Meneu JC; Lumbreras C; Solís-Herruzo JA; Moreno E Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125 [TBL] [Abstract][Full Text] [Related]
14. Hepatitis C. Burra P Semin Liver Dis; 2009 Feb; 29(1):53-65. PubMed ID: 19235659 [TBL] [Abstract][Full Text] [Related]
15. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. Bhoori S; Toffanin S; Sposito C; Germini A; Pellegrinelli A; Lampis A; Mazzaferro V J Hepatol; 2010 May; 52(5):771-5. PubMed ID: 20347502 [TBL] [Abstract][Full Text] [Related]